In a mouse model, BRAFV600E induced expression of CCL2, an immunosuppressive chemokine, while PLX4720 treatment downregulated tumor CCL2 gene expression and increased numbers of CD8 TILs [283]. Here, CCL2 is linked to neoplasm.